ASADZADEH, FATEMEH
 Distribuzione geografica
Continente #
NA - Nord America 85
EU - Europa 81
AS - Asia 35
AF - Africa 5
SA - Sud America 2
Totale 208
Nazione #
US - Stati Uniti d'America 83
IT - Italia 64
SG - Singapore 21
NL - Olanda 9
VN - Vietnam 8
DE - Germania 6
CI - Costa d'Avorio 5
CN - Cina 4
BR - Brasile 2
CA - Canada 2
IN - India 2
FR - Francia 1
GB - Regno Unito 1
Totale 208
Città #
Naples 21
Singapore 20
Chandler 17
Ashburn 10
Amsterdam 8
Dong Ket 8
Battipaglia 7
Napoli 6
Millbury 5
Munich 5
Boston 3
Lawrence 3
Pomigliano D'arco 3
Campinas 2
Caserta 2
Indore 2
Los Angeles 2
Marano di Napoli 2
Portici 2
Quartu Sant'elena 2
Santa Clara 2
Bari 1
Des Moines 1
Fara Novarese 1
Fort St. James 1
Genoa 1
Mugnano di Napoli 1
Nanjing 1
Nottingham 1
Palermo 1
Princeton 1
Rende 1
Salerno 1
Scafati 1
Shanghai 1
Toronto 1
Warmond 1
Washington 1
Wilmington 1
Totale 150
Nome #
In vivo bioluminescence imaging using orthotopic xenografts towards patient's derived-xenograft Medulloblastoma models 45
A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer 42
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 42
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 36
DDDR-32. A NEW IMMUNOMODULATORY FUNCTION OF PYRIDO-PYRIMIDINE DERIVATIVES TO IMPAIR METASTATIC GROUP 3 MEDULLOBLASTOMA IN VIVO 30
Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules 12
Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication 7
International patent: PCT/EP2023/079960 - WO/2024/089190 - EP4361137; “Prune_1 inhibitors and therapeutic use thereof” 5
Totale 219
Categoria #
all - tutte 1.152
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.152


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 1 0 0 0 0 0 4 2 0 0 0 8
2021/202241 3 0 1 0 1 0 6 1 5 1 11 12
2022/202355 4 0 2 1 9 6 0 3 15 8 4 3
2023/202460 5 5 10 7 3 4 8 9 1 2 5 1
2024/202542 8 3 7 13 11 0 0 0 0 0 0 0
Totale 219